Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

Inclusion Criteria: 3-Dose Safety Population * Female 9-26 years at the time of first dose of GARDASIL™ * Completed the 3-dose regimen of GARDASIL™ per protocol Pregnancy Safety Population * Received at least one dose of GARDASIL™ up to 30 days prior to the date of conception or any time between conception and the day of pregnancy resolution Autoimmune Safety Population * Female who has received at least one dose of GARDASIL™ * Has been a member of same Managed Care Organization (MCO) for at least 12 months prior to the receipt of GARDASIL™ Any Dose Safety Population * Female who has received at least one dose of GARDASIL™ Exclusion Criteria: 3-Dose Safety Population * Male * Receives incomplete regimen of GARDASIL™ * Completes the three dose regimen of GARDASIL™ in more than 12 months * Less than 28 day interval between doses 1 and 2 or less than a 12 week interval between doses 2 and 3 * Younger than 9 or older than 26 years of age at receipt of first dose Pregnancy Safety Population * Males * No record of pregnancy at the Managed Care Organization (MCO) Autoimmune Safety Population * Member of the same MCO for less than 12 months prior to receiving the first dose * Male